We initiate coverage on Revolution Medicines with a Sell rating and a $158.00 price target. At $193.80, the stock's $38.3 billion enterprise value discounts unproven pipeline indications while 2026-2027 operating expenses exceed $2.1 billion annually.
Key points
- $38.3 billion in enterprise value prices in dominant market share across four unproven frontline cancer indications beyond its newly approved second-line pancreatic indication.
- $2.15 billion in 2026 operating expenses outpaces early commercial receipts, locking the company into heavy cash burn through 2027 despite $3.94 billion in liquidity.
- $158.00 price target reflects 25.4 times 2027 projected net sales, offering an 18.5% downside as commercial execution confronts massive clinical spend.
The call
The market prices Revolution Medicines as an established commercial oncology powerhouse rather than a newly commercialized biotech with a single approved indication. At $193.80, the current enterprise value requires daraxonrasib to capture over $5.0 billion in peak sales across lung, pancreatic, and colorectal cancers while maintaining extraordinary operating margins.
Quarterly revenue ramp versus escalating operating expenses ($M)- Reported net revenue
- Desk projected net revenue
- Reported operating expenses
- Desk projected operating expenses
Company quarterly reports through Q2 2026; desk projections for H2 2026E and FY 2027E.
We project commercial RASONQUE net sales will reach $1.30 billion in 2027, offset by $2.60 billion in operating expenses and heavy royalty obligations. Operating losses of $1.46 billion in 2027 will erode net cash, leaving the stock vulnerable to valuation compression as clinical trials expand.
Sum-of-the-parts valuation bridge to twelve-month equity value ($B)Desk risk-adjusted sum-of-the-parts model 12 months forward (October 2027).
Valuation
Our $158.00 12-month target values Revolution Medicines at 25.4 times 2027 projected net product revenue of $1.30 billion. Adding projected year-end 2027 net cash of $2.05 billion yields a $35.1 billion equity value, or $158.00 per share across 222.0 million diluted shares. A sum-of-the-parts pipeline valuation confirms fair value closer to $99.38 per share.
| Valuation metric | Value |
|---|
| 2027 projected net product revenue | $1.30 billion |
| Target enterprise value multiple | 25.4 times |
| Twelve-month enterprise value | $33.0 billion |
| Projected year-end 2027 net cash | $2.05 billion |
| Twelve-month equity value | $35.1 billion |
| Diluted share count | 222.0 million |
| Twelve-month price target | $158.00 |
A 25.4 times forward revenue multiple remains historically generous for commercial biotechnology launches. Even under this premium valuation, the stock carries an 18.5% downside risk. The risk-reward asymmetry favors a Sell rating as launch reality tempers enthusiasm.
Risks
- Rapid commercial conversion of 2,000 expanded-access pancreatic cancer patients could generate higher early revenue, visible in quarterly product net sales.
- Phase 3 RASolve 301 NSCLC combination data could exceed efficacy hurdles, visible in hazard ratios below 0.50 in second-half 2027 readouts.
- Strategic acquisition interest from large pharmaceutical buyers seeking comprehensive RAS platform assets could support shares, visible in partnership disclosures.
What would change my mind
We would turn positive if RASONQUE net sales exceed $500 million within its first two quarters while full-year 2027 cash burn narrows below $800 million.
